News

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA) orp ...
Daily28m
Post WHO alert, Novo Nordisk seeks EMA nod for higher dose of obesity treatment Wegovy
Novo Nordisk has announced the submission of an application to the European Medicines Agency (EMA) for approval of a new, ...